JohnDwyerPowderlyIIMD
Oncology • Huntersville, NCAssistant Consulting Professor in the Department of Medicine, Duke University School of Medicine
Are you Dr. Powderly?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 61 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
9801 Kincey Ave
Suite 145
Huntersville, NC 28078Phone+1 704-947-6599Fax+1 704-947-6597- Is this information wrong?
Summary
- Dr. John Powderly II, MD is an oncologist in Huntersville, North Carolina. He is currently licensed to practice medicine in North Carolina and Texas. He is affiliated with Novant Health Presbyterian Medical Center and is an Assistant Consulting Professor in the Department of Medicine at Duke University School of Medicine.
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2000 - 2002
University of Texas Health Science Center at HoustonResidency, Internal Medicine/Pediatrics, 1995 - 1999
Georgetown University School of MedicineClass of 1995
Certifications & Licensure
NC State Medical License 2000 - 2024
TX State Medical License 1997 - 2001
Clinical Trials
- A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
- A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells. Start of enrollment: 2007 Nov 01
- A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) Start of enrollment: 2017 May 02
Publications & Presentations
PubMed
- First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas B Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, R...> ;Cancer Research Communications. 2024 Mar 29
- Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a P...Edward B Garon, Alexander I Spira, Sarah B Goldberg, Jamie E Chaft, Vassiliki Papadimitrakopoulou, Tina Cascone, Scott J Antonia, Julie R Brahmer, D Ross Camidge, John...> ;Journal of Thoracic Oncology. 2023 Aug 1
- 4 citationsPhase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.Aung Naing, Alain P Algazi, Gerald S Falchook, Benjamin C Creelan, John Powderly, Seth Rosen, Minal Barve, Niharika B Mettu, Pierre L Triozzi, John Hamm, Gongfu Zhou, ...> ;Cancer. 2023 Jan 1
- Join now to see all
Press Mentions
Tempest Therapeutics' Oncology Programs Presented at Society of Immunotherapy for Cancer Annual MeetingNovember 8th, 2019
Community Practices Say Moonshot May SputterMarch 4th, 2016
Professional Memberships
- Member
Hospital Affiliations
Novant Health Presbyterian Medical CenterCharlotte, North Carolina
